AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, BidAskClub reports.

Several other research analysts have also recently weighed in on AMAG. Barclays reiterated a “hold” rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. ValuEngine cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. SunTrust Banks restated a “hold” rating and issued a $8.00 price target on shares of TrueCar in a research report on Tuesday, May 14th. Zacks Investment Research upgraded Hanmi Financial from a “sell” rating to a “hold” rating in a research report on Thursday, June 20th. Finally, Cowen restated a “hold” rating and issued a $13.00 price target on shares of AMAG Pharmaceuticals in a research report on Monday, June 24th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $16.92.

AMAG stock opened at $8.65 on Tuesday. The company has a current ratio of 2.30, a quick ratio of 2.13 and a debt-to-equity ratio of 0.44. The stock’s fifty day moving average price is $9.46. AMAG Pharmaceuticals has a fifty-two week low of $7.81 and a fifty-two week high of $26.10.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.77). The firm had revenue of $75.80 million for the quarter, compared to the consensus estimate of $90.13 million. AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The firm’s quarterly revenue was down 35.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.59) EPS. As a group, equities analysts expect that AMAG Pharmaceuticals will post -2.15 EPS for the current fiscal year.

In other AMAG Pharmaceuticals news, insider Elizabeth Scott Bolgiano acquired 5,000 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, May 9th. The shares were acquired at an average cost of $10.93 per share, with a total value of $54,650.00. Following the completion of the purchase, the insider now directly owns 74,847 shares of the company’s stock, valued at approximately $818,077.71. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Armistice Capital, Llc acquired 44,000 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, June 27th. The stock was acquired at an average cost of $9.52 per share, for a total transaction of $418,880.00. The disclosure for this purchase can be found here. Insiders purchased 328,016 shares of company stock worth $2,904,577 in the last 90 days. 4.90% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can boosted its stake in AMAG Pharmaceuticals by 12.3% in the fourth quarter. Great West Life Assurance Co. Can now owns 44,924 shares of the specialty pharmaceutical company’s stock valued at $629,000 after buying an additional 4,919 shares in the last quarter. NumerixS Investment Technologies Inc boosted its stake in AMAG Pharmaceuticals by 17.8% in the first quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 1,083 shares in the last quarter. Two Sigma Investments LP boosted its stake in AMAG Pharmaceuticals by 129.3% in the fourth quarter. Two Sigma Investments LP now owns 250,589 shares of the specialty pharmaceutical company’s stock valued at $3,806,000 after buying an additional 141,286 shares in the last quarter. Strs Ohio boosted its stake in AMAG Pharmaceuticals by 30.1% in the first quarter. Strs Ohio now owns 51,400 shares of the specialty pharmaceutical company’s stock valued at $662,000 after buying an additional 11,900 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in AMAG Pharmaceuticals by 1.1% in the first quarter. Rhumbline Advisers now owns 103,866 shares of the specialty pharmaceutical company’s stock valued at $1,338,000 after buying an additional 1,125 shares in the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Recommended Story: How to use beta for portfolio diversification

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.